TrialCancer chemotherapy and pharmacology2013

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Emmanuel S Antonarakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.